0001213900-22-000963.txt : 20220106 0001213900-22-000963.hdr.sgml : 20220106 20220106163026 ACCESSION NUMBER: 0001213900-22-000963 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220102 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allarity Therapeutics, Inc. CENTRAL INDEX KEY: 0001860657 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41160 FILM NUMBER: 22515149 BUSINESS ADDRESS: STREET 1: 210 BROADWAY STREET 2: SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 401-426-4664 MAIL ADDRESS: STREET 1: 210 BROADWAY STREET 2: SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 ea153620-8k_allarity.htm CURRENT REPORT
0001860657 false 0001860657 2022-01-02 2022-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 2, 2022

 

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in our charter)

 

Delaware   001-41160   87-2147982
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)  

(IRS Employer

Identification No.)

 

210 Broadway, Suite 201

Cambridge, MA

   02139
(Address of Principal Executive Offices)   (Zip Code)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On January 2, 2022, Allarity Therapeutics A/S, an Aktieselskab organized under the laws of Denmark (“Allarity A/S”) entered into certain exclusive license agreements (collectively, the “License Agreements”) with Oncoheroes Biosciences, Inc. (“Oncoheroes”). As previously disclosed, on December 20, 2021 and in connection with the Plan of Reorganization and Asset Purchase Agreement which was amended and restated on September 23, 2021 (the “Recapitalization Share Exchange”), between Allarity Therapeutics, Inc. (“us,” “we,” “our,” or the “Company”), Allarity Acquisition Subsidiary, Inc., a Delaware corporation and our wholly owned subsidiary (“Acquisition Sub”), and Allarity A/S, we consummated the transactions contemplated in the Asset Purchase Agreement among us, Acquisition Sub and Allarity A/S (the “Purchase Agreement”), pursuant to which Acquisition Sub acquired substantially all of the assets and assumed substantially all of the liabilities of Allarity A/S. In accordance with Section 13.03 of the Purchase Agreement, effective as of January 2, 2022, we entered into an Assignment and Assumption Agreement with Allarity A/S, pursuant to which Allarity A/S assigned the License Agreements to us (the “Assignment”).

 

Under the License Agreements, Oncoheroes will acquire exclusive, global development rights to our therapeutic candidates Dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and Stenoparib, a PARP inhibitor, and assume responsibility for their further clinical development in the field of pediatric cancers. As part of the License Agreements, Oncoheroes will receive commercialization rights for pediatric cancers, subject to our first buy-back option for each program, and we will receive upfront license fees and regulatory milestones for each program. If we do not re-acquire the pediatric field rights, we will further receive certain clinical/regulatory milestone payments and royalties on sales of Stenoparib and Dovitinib in the pediatric cancer market from Oncoheroes.

 

Development Milestone Payments

 

Under the License Agreements, we would also be entitled to receive certain milestone payments relating to the development and commercialization of Dovitinib and Stenoparib upon the occurrence of the following events: (i) upon the regulatory approval of a product in the United States, and (ii) upon the regulatory approval of a product in the European Union. Each milestone payment is payable one time only, regardless of the number of times the corresponding milestone event is achieved by a product and regardless of the number of products to achieve such milestone event. If all milestones are achieved, then we would be entitled to receive up to $2 million in milestone payments under each respective License Agreement.

 

Royalty Payments

 

In addition to the milestone payments described above, Oncoheroes has agreed to pay us royalties based on aggregate annual net sales of all products derived from Dovitinib and Stenoparib during the royalty term which is determined on a country-by-country and product-by-product basis, as the period of time commencing on the first commercial sale of any product in such country and expiring upon the latest of (a) the expiration of the last valid claim of a patent within (i) our intellectual property and/or (ii) the joint intellectual property in such country (if, but only if, such joint intellectual property arose from activities under the clinical development plan defined in the agreement), or (b) the fifteenth (15th) anniversary of the date of first commercial sale of such licensed drug in such country. We will be entitled to royalty payments of between three percent (3%) and eight percent (8%) of annual net sales of between $0 and $100 million, between six percent (6%) and eleven percent (11%) of annual net sales between $100 million and $200 million, and between eight percent (8%) and thirteen percent (12%) of annual net sales in excess of $200 million. The royalty amounts we are entitled to receive may be subject to reduction in the event a product is not covered by a valid claim of a licensed patent in such country.

 

1

 

 

The License Agreements with Oncoheroes will continue on a product-by-product and country-by-country basis until the expiration of the applicable royalty term described above. However, the License Agreements may be terminated by Oncoheroes at any time after the first anniversary of the effective date of each License Agreement for any or no reason upon (i) ninety (90) days’ written notice if such notice is provided prior to first commercial sale, and (ii) one hundred eighty (180) days’ written notice if such notice is provided on or after the first commercial sale. We may also terminate the License Agreements upon sixty (60) days’ written notice if Oncoheroes challenges any of our licensed patents included under the License Agreements. The License Agreements may also be terminated by either party upon the material breach of the agreement by the other party if such breach is not cured within sixty (60) days, or in the event that either party files for bankruptcy.

 

The foregoing summary of the terms of the License Agreements and Assignment do not purport to be complete. Copies of the License Agreements (in redacted form subject to a confidential treatment request submitted to the Securities and Exchange Commission (the “SEC”)) and Assignment will be filed as Exhibits to the Company’s Form 10-K to be filed for the year ended December 31, 2021.

 

Item 7.01 Regulation FD Disclosure

 

On January 3, 2022, the Company issued a joint press release announcing the signing of the License Agreements. A copy of the full text of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

 

The information reported Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Report on Form 8-K contains certain statements that are, or may be deemed to be, “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements that are purely historical are forward-looking statements. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees for future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. All forward-looking statements in this document are qualified in their entirety by this cautionary statement.

 

2

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Exhibit Description
99.1   Press Release dated January 3, 2022 – Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned hereunto duly authorized.

 

  Allarity Therapeutics, Inc.
   
  By: /s/ Steve R. Carchedi
    Steve R. Carchedi
    Chief Executive Officer
     
Dated: January 6, 2022    

 

 

4

 

 EX-99.1 2 ea153620ex99-1_allarity.htm PRESS RELEASE DATED JANUARY 3, 2022 - ALLARITY THERAPEUTICS AND ONCOHEROES BIOSCIENCES SIGN AGREEMENTS TO ADVANCE PEDIATRIC CANCER DEVELOPMENT OF DOVITINIB AND STENOPARIB

Exhibit 99.1

 

 

 

Press release

 

Allarity Therapeutics and Oncoheroes Biosciences Sign
Agreements to Advance Pediatric Cancer Development
of Dovitinib and Stenoparib

 

Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity’s DRP® companion diagnostics

 

Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic

 

Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc. (“Oncoheroes”), a clinical-stage biotechnology company advancing new therapies for childhood cancers, today announced that they have entered into licensing agreements under which Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor, and assume responsibility for their further clinical development in pediatric cancers.

 

Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers. Oncoheroes will take responsibility for pediatric cancer clinical development activities for both clinical-stage therapeutics. Allarity will support Oncoheroes’ pediatric clinical trials by providing clinical-grade drug inventory at cost and by facilitating DRP® companion diagnostic screening of pediatric patients for each drug. Under the licenses, Oncoheroes will receive commercialization rights for pediatric cancers, subject to Allarity’s first buy-back option for each program, and Allarity will receive an undisclosed upfront license fee and regulatory milestones for each program. If Allarity does not re-acquire the pediatric field rights, it will further receive certain clinical/regulatory milestone payments and royalties on sales of stenoparib and dovitinib in the pediatric cancer market from Oncoheroes. Further financial terms of the licenses were not disclosed.

 

Steve R. Carchedi, CEO of Allarity Therapeutics, commented, “We are very pleased to partner with Oncoheroes Biosciences to advance both dovitinib and stenoparib as potential new therapeutic options for the personalized treatment of children and adolescents with cancer. Oncoheroes is a leader in advancing new therapeutics to help address historically underserved, rare childhood cancers, and an ideal partner for Allarity in the pediatric cancer market. Our out-licensing of these pediatric development programs enables Allarity to remain focused on our top priority programs in adult cancers, while at the same time leveraging Oncoheroes’ resources, capabilities, and commitment to clinically advancing dovitinib and stenoparib in childhood cancers, together with our DRP® companion diagnostics, in a true personalized cancer care approach.”

 

Allarity Therapeutics, Inc.    |    210 Broadway, #201    |    Cambridge, MA    |    U.S.A.    |    NASDAQ: ALLR    |    www.allarity.com

 

Page 1 of 4

 

 

In December 2021, Allarity submitted an NDA, to the U.S. Food and Drug Administration (FDA), for marketing approval for dovitinib for the treatment of third line RCC. In April 2021, the Company submitted a premarket approval (PMA) application for use of its Dovitinib-DRP® companion diagnostic to select and treat patients most likely to respond to dovitinib. In support of its NDA filing, and in accordance with FDA requirements, the Company is also planning a clinical trial of dovitnib in pediatric patients with osteosarcoma, in partnership with Oncoheroes, where the patients will be selected with the Dovitinib-DRP® companion diagnostic. Allarity’s focus on pediatric osteosarcoma development is based on the results of two previously reported preclinical studies in which treatment with dovitinib, compared to control treatment (sucrose solution lacking dovitinib), increased the median survival time of mouse models of osteosarcoma by 50% and antitumor growth activity was observed for dovitinib as a single agent.

 

Ricardo Garcia, CEO & Founder of Oncoheroes Biosciences, further commented, “Oncoheroes is a mission-driven company committed to deliver more effective and safer treatments for children and adolescents with cancer. We are excited to partner with Allarity on these co-development programs. These fit perfectly with our goal of becoming the partner of choice for life sciences companies with drug candidates that have the potential to treat pediatric cancers. We are confident that this collaborative model will create powerful synergies to accelerate pediatric drug development and bring tangible benefits to younger cancer patients.”

 

Allarity is currently evaluating stenoparib for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute (Boston, MA U.S.A.), and additional U.S. and European trial sites, using the Stenoparib-DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome. In prior clinical testing of more than 60 patients, stenoparib was well tolerated with a demonstrated acceptable safety profile. Through use of DRP® patient selection, Allarity aims to provide a superior clinical benefit to ovarian cancer patients receiving stenoparib as compared to other approved PARP inhibitors. Moreover, there is increasing evidence pointing to the potential use of PARP inhibitors in the treatment of various pediatric cancers.

 

About Allarity Therapeutics

 

Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of five drug candidates, including: Stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; Dovitinib, a pan-TKI submitted for NDA review by the FDA for the 3rd line treatment of renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. for the 2nd line treatment of metastatic breast cancer and in Phase 2 development, in Europe, for the treatment of the same indication; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 development for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM). The LiPlaCis® and 2X-111 programs are partnered, via out-license, to Smerud Medical Research International AS. In 2021, Allarity sold the global rights to Irofulven, a DNA-damaging agent in Phase 2 for prostate cancer, back to Lantern Pharma, Inc. The Company maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the company’s website at www.Allarity.com

 

Allarity Therapeutics, Inc.    |    210 Broadway, #201    |    Cambridge, MA    |    U.S.A.    |    NASDAQ: ALLR    |    www.allarity.com

 

Page 2 of 4

 

 

About the Drug Response Predictor – DRP® Companion Diagnostic

 

Allarity uses its drug-specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP® score, the therapeutic response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP® is based on messenger RNA from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.

 

Follow Allarity on social media

 

Facebook: https://www.facebook.com/AllarityTx/

LinkedIn: https://www.linkedin.com/company/allaritytx/

Twitter: https://twitter.com/allaritytx

 

About Oncoheroes Biosciences

 

Oncoheroes is a ground-breaking biotech company exclusively focused on the discovery and development of better drugs for children and adolescents with cancer. Our vision is to deliver benefits to young cancer patients and create value in the process. The company is headquartered in Boston, US, with a discovery lab in Barcelona, Spain. Oncoheroes is actively looking for in-licensing opportunities in the pediatric oncology space while working to generate new proprietary assets for a number of pediatric cancer indications with high unmet medical needs. For more information please visit: oncoheroes.com

 

Follow Oncoheroes on social media

 

Facebook: https://www.facebook.com/Oncoheroes

LinkedIn: https://www.linkedin.com/company/oncoheroes

Twitter: https://twitter.com/oncoheroesbio

Instagram: https://www.instagram.com/oncoheroesbio

 

Forward-looking statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements relating to the submitted NDA for dovitinib and PMA for the drug-specific DRP® companion diagnostic for dovitinib, future clinical trials for dovitinib in pediatric cancers, development of dovitinib with an indication for osteosarcoma based on preclinical studies, ongoing clinical trials for stenoparib for the treatment of advanced ovarian cancer, and statements relating to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib, the drug-specific DRP® companion diagnostic for dovitinib, or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form S-1 registration statement on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

 

###

 

Allarity Therapeutics, Inc.    |    210 Broadway, #201    |    Cambridge, MA    |    U.S.A.    |    NASDAQ: ALLR    |    www.allarity.com

 

Page 3 of 4

 

 

Company Contact:

 

Jens Knudsen

Chief Financial Officer

investorrelations@allarity.com

 

Investor Relations:

 

Chuck Padala

LifeSci Advisors

+1 (646) 627-8390

chuck@lifesciadvisors.com

 

U.S. Media Contact:

 

Mike Beyer
Sam Brown, Inc.
+1 (312) 961-2502
mikebeyer@sambrown.com

 

EU Media Contact:

 

Thomas Pedersen

Carrotize PR & Communications

+45 6062 9390

tsp@carrotize.com

 

Allarity Therapeutics, Inc.    |    210 Broadway, #201    |    Cambridge, MA    |    U.S.A.    |    NASDAQ: ALLR    |    www.allarity.com

 

 

Page 4 of 4

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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allr-20220102.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 allr-20220102_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 allr-20220102_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 02, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 02, 2022
Entity File Number 001-41160
Entity Registrant Name ALLARITY THERAPEUTICS, INC.
Entity Central Index Key 0001860657
Entity Tax Identification Number 87-2147982
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 210 Broadway
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 401
Local Phone Number 426-4664
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ALLR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea153620-8k_allarity_htm.xml IDEA: XBRL DOCUMENT 0001860657 2022-01-02 2022-01-02 iso4217:USD shares iso4217:USD shares 0001860657 false 8-K 2022-01-02 ALLARITY THERAPEUTICS, INC. DE 001-41160 87-2147982 210 Broadway Suite 201 Cambridge MA 02139 401 426-4664 false false false false Common Stock, par value $0.0001 per share ALLR NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://allarity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea153620-8k_allarity.htm allr-20220102.xsd allr-20220102_lab.xml allr-20220102_pre.xml ea153620ex99-1_allarity.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea153620-8k_allarity.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea153620-8k_allarity.htm" ] }, "labelLink": { "local": [ "allr-20220102_lab.xml" ] }, "presentationLink": { "local": [ "allr-20220102_pre.xml" ] }, "schema": { "local": [ "allr-20220102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ALLR", "nsuri": "http://allarity.com/20220102", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea153620-8k_allarity.htm", "contextRef": "From2022-01-02to2022-01-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://allarity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea153620-8k_allarity.htm", "contextRef": "From2022-01-02to2022-01-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://allarity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001213900-22-000963-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-000963-xbrl.zip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end